Related Experiment Video
Updated: Jul 9, 2025

08:36
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
553
Rasmussen's Encephalitis: A Literary Review.
Abhishek Kumar1, Harshil Krishnani1, Arundhati Pande1
1Medical Education, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus
|November 29, 2023
Summary
Rasmussen's encephalitis (RE) is a rare brain inflammation. Ongoing research seeks its viral or autoimmune cause to improve diagnosis and immunotherapy for this condition.
Area of Science:
- Neurology
- Immunology
- Pathology
Background:
- Rasmussen's encephalitis (RE) is a rare, persistent inflammatory brain disease.
- Its exact cause remains unclear, with theories including viral infections, autoantibodies, and T-cell reactions.
- Histopathology reveals cortical inflammation, neuronal damage, and gliosis specific to one hemisphere.
Purpose of the Study:
- To investigate the underlying immunological or viral components of Rasmussen's encephalitis.
- To improve early diagnosis and assess the primary nature of observed pathological phenomena.
- To guide the development of effective immunotherapy and treatment strategies.
Main Methods:
- Review of existing literature on Rasmussen's encephalitis etiology and pathology.
- Discussion of diagnostic challenges and current treatment limitations.
- Emphasis on the need for combined clinical, genetic, and histological studies.
Main Results:
- Current understanding points to a cytotoxic T-cell reaction against neurons as a likely cause.
- Diagnosis relies on characteristic histopathological findings of hemispheric inflammation and neuronal degeneration.
- Surgical hemispherectomy is the only effective treatment for severe seizures, though immunotherapy research is ongoing.
Conclusions:
- Further research is crucial to identify the primary triggers of RE for better treatment outcomes.
- Developing accurate diagnostic tools and effective immunotherapies are key priorities.
- Establishing in vitro and animal models is essential for studying causality and directing clinical trials.

